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Abstract 
Objective: Describe the profile and clinical indicators of people from a domiciliary 
anticoagulation program in the city of Bogota, during a year of monitoring. Materials 
and methods: Quantitative study of descriptive scope. The population was made of 
66 people from the program, who met the inclusion criteria and were cared for a 
year. Some of the measured variables were: type of anticoagulant, anticoagulation 
indications, functional compromise, risk of bleeding and time in therapeutic range. 
The information was obtained from monthly statistics from the program, univariate 
analyzed, reporting frequency distributions and ethical aspects were protected for the 
health research. Results: 66 patients older than 60 years of age that received Warfa-
rin were attended and the main symptom was atrial fibrillation. The patients reached 
the therapeutic target in the first 9 days, achieving 70% of time in the therapeutic 
range, and no adverse events were presented although being at intermediate-high 
risk of bleeding, severe functional detriment and high comorbidity. Conclusion: The 
permanent monitoring of coagulation time, availability of additional controls, fast ad-
justments in the anticoagulation doses, health education and a direct communication 
channel between the patient, the family, and the healthcare team, could improve the 
clinical indicators of anticoagulated patients. 
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Resumen 
Objetivo: Describir el perfil e indicadores clínicos de las personas pertenecientes a 
un programa domiciliario de anticoagulación en la ciudad de Bogotá, durante un año 
de seguimiento. Materiales y métodos: Estudio cuantitativo de alcance descriptivo. 
La población estuvo integrada por 66 personas pertenecientes al programa, quienes 
cumplieron los criterios de inclusión y fueron atendidas durante un año. Algunas va-
riables medidas fueron: tipo de anticoagulante, indicación de anticoagulación, com-
promiso funcional, riesgo de sangrado y tiempo en rango terapéutico. La información 
fue obtenida de la estadística mensual del programa, analizada de forma univariada, 
reportando distribución de frecuencias, y se salvaguardaron los aspectos éticos para 
la investigación en salud. Resultados: Se atendieron 66 pacientes mayores de 60 
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años que recibían warfarina y la indicación principal fue fibrilación auricular. Las personas alcan-
zaron la meta terapéutica en los primeros 9 días, logrando un 70 % del tiempo en rango terapéutico, 
y no se presentaron eventos adversos a pesar de tener riesgo intermedio-alto de sangrado, deterioro 
severo de la funcionalidad y alta comorbilidad. Conclusión: El monitoreo permanente de tiempos de 
coagulación, disponibilidad de controles adicionales, ajustes rápidos en la dosis de anticoagulante, 
educación en salud y un canal directo de comunicación entre el paciente, la familia y el equipo de 
salud, podrían mejorar los indicadores clínicos de las personas anticoaguladas. 
Palabras Clave: Anticoagulantes, pacientes, visita domiciliaria, atención de enfermería.
Resumo 
Objetivo: Descrever o perfil e indicadores clínicos das pessoas que conformam um programa de as-
sistência domiciliar de anticoagulação na cidade de Bogotá, realizada em um ano de acompanhamen-
to. Materiais e métodos: Estudo quantitativo descritivo. A amostra esteve composta por 66 pessoas 
que pertenceram ao programa e foram acompanhadas por um ano. Algumas variáveis aferidas foram: 
tipo de anticoagulante, indicações da anticoagulação, comprometimento funcional, risco de sangra-
mento e tempo no rango terapêutico. As aferições realizaram-se todo mês e a análise realizou-se de 
forma univariada, reportando distribuições de frequências. Foram considerados os aspectos éticos 
para a pesquisa em saúde. Resultados: Atenderam-se 66 pessoas maiores de 60 anos que receberam 
warfarina e a indicação foi  o diagnóstico de fibrilação auricular. As pessoas conquistaram as metas 
terapêuticas e não apresentaram complicações nos primeiros 9 dias de tratamento, além de obter 70% 
de tempo do rango terapêutico. Também não houve eventos adversos embora o risco intermeio-alto 
de sangramento, deterioro da funcionalidade ou alta morbidade. Conclusão: O acompanhamento 
permanente dos tempos de coagulação, a disponibilidade de atendimentos adicionais, ajustes rápidos 
nas dosagens do anticoagulante, a educação em saúde e a comunicação direta entre o paciente à 
família e a equipe de saúde, poderão melhorar os indicadores clínicos das pessoas anticoaguladas. 
Palavras-chave: Anticoagulantes, pacientes, assistência domiciliar, cuidados de enfermagem.
Introduction 
Venous thromboembolism, mainly Deep vein throm-
bosis (DVP), and pulmonary embolism (PE), in addi-
 tion to factors such as atrial fibrillation (AP), cardiac 
valve replacement, ischemic stroke and coagulation 
disorders, become increasingly frequent indicators 
for the use of oral anticoagulants.
DVP and EP occupy the first places of morbimorta-
lity, along with heart attack, stroke, coronary artery 
disease, and shock (1).
According to studies, the incidence of venous throm-
boembolism is of 117 cases per 100,000 inhabitants, 
and with age, the number of cases increases signifi-
cantly (2). Also, it’s the third cause of cardiovascular 
disease in Europe and North America. For the speci-
fic case of EP, the incidence is estimated to be 95 per 
100,000 inhabitants (3).
In the case of atrial fibrillation, this is globally con-
sidered the most prevalent sustained supraventricular 
tachycardia, affecting 1 to 2 percent of the popula-
tion, representing a serious public health problem due 
to the impact in survival and life quality of the pa-
tients (4).
In the case of heart valve disorders, the aortic steno-
sis is currently the disease that most frequently deter-
mines a valve replacement (5), after the immediate 
post-operatory it becomes an absolute indication of 
anticoagulation. 
In relation to strokes, the World Health Organization 
(WHO) reassures it caused 15 million deaths in 2015, 
and along with coronary artery disease, have been 
the main cause of mortality for the last 15 years (6). 
The calculated incidence for Latin America varies 
between 35 and 183 cases per 100,000 inhabitants. 
In Colombia, a study made in Antioquia reported dan 
annual incidence adjusted by age and gender of 88.9 
cases per 100,000 inhabitants, affecting more men 
than women (7). 
Thrombophilia is defined, as a coagulation disor-
der that increases the predisposition of formation of 
blood clots, significantly increasing the morbidity 
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and mortality and presenting a prevalence between 
1-3/100,000 people, annually (8).  
Oral anticoagulants were discovered at the beginning 
of the twentieth century and have been constituted as 
the main therapy for more than 50 years (9), prescri-
bed for venous thromboembolism (DVP, EP), atrial 
fibrillation, arterial thrombosis, ischemic stroke, me-
chanical valve replacement and thrombophilia (10, 
11).
Warfarin is known as one of the most used anticoa-
gulants, in virtue of its high efficiency. However, the 
limitations for its use are known, such as the narrow 
therapeutic range and its fluctuation, the risk of blee-
ding due to over anticoagulation, the interactions with 
other medicine and foods, and also the necessity of 
regular monitoring from the International Normali-
zed Ratio (INR) (12, 13).  
In that sense, a study of cost- effectiveness descri-
bed that, traditionally, oral antagonists of vitamin K 
(AVK) have been used for this purpose, but require 
frequent adjustments and have a strict therapeutic in-
terval that makes its usage difficult, therefore substi-
tutes have been searched, introducing to the medical 
practice in the last decade new oral anticoagulants 
(NACO), at least as effective as AVK, but with a hig-
her price (14). 
An ideal oral anticoagulant should be administered in 
fixed doses, with less interactions, greater efficiency 
and high security, this way decreasing the risks of he-
morrhage, without needing such strict control as re-
quired by AVK, and overall, have an antidote to revert 
its effect in case of emergency (15). 
Parallel to the search of an ideal medicine, healthcare 
providers have designed and implemented accom-
panying programs for anticoagulated patients, which 
are performed both in the hospital (ambulatory) and 
also, for a few years at the residence of the patient.
These programs are called “clinics or anticoagulation 
programs” and are built by an interdisciplinary team 
whose main goal is to guarantee the success of the 
anticoagulation therapy through comprehensive care 
of the person, with strategies such as periodic medical 
evaluation, accompaniment, education and perma-
nent monitoring.
An example of this program, in Colombia, is develo-
ped at the Vicente de Paul University Hospital, which 
claims that the key point strategy used by its anticoa-
gulation clinic focused on verifying and establishing 
the therapeutic indication, defining the time and dura-
tion of the anticoagulation therapy and the therapeu-
tic range in which the INR wants to be maintained, 
as well as providing education both to the patient and 
the person or family member in charge of  its care, 
evaluating the adherence and constant vigilance of 
new thrombotic events and bleeding (16). 
Another example is the Anticoagulation Clinic of the 
Clinical Foundation of the Valle de Lili, which bases 
their interventions in education, control and follow-
up of the patients receiving Warfarin. Also, the expe-
rience at the Anticoagulation Clinic at the Fundacion 
de Santa Fe University Hospital in Bogota, which 
between 2008 and 2012 has attended 159 patients 
(17). 
Finally, in the city of Bogota, the anticoagulation 
program aimed for this study, orientates its program 
towards people with reduced functional abilities, a 
phenomenon that impedes access to hospital health-
care providers, leading to providing care at the place 
of residence of the patient.
Domiciliary care in Colombia is defined, according to 
the current regulations, as an independent and auto-
nomous service of a healthcare provider for the han-
dling of acute or chronic patients in the domiciliary 
environment, with controlled criteria, in which activi-
ties and procedures proper of health care services are 
developed, provided in the place of residence of the 
patient, with the support of professionals, specialists, 
and the participation of the family or caregiver (18). 
The anticoagulation program of the healthcare pro-
vider object of study, differentiates from the others 
because it is performed at the residence of the patient, 
oriented to the anticoagulated patient and specially to 
the caregivers, since most of the time they are in char-
ge of administering the medicine and the diet, and 
also of being the first to recognize alarm symptoms 
of hypercoagulation or over anticoagulation. The pro-
gram is in charge of an internist, a postgraduate nurse 
and two nursing assistants with specific training in 
the area. The criteria a person must meet to get into 
the program are: have a Barthel scale lower or equal 
to 60 and presenting a pathology that requires anti-
coagulant therapies.
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Every person that gets into the program, along with 
their family or caregivers, receive health education 
focusing on aspects related to the safe use of anti-
coagulants, indications, therapy duration and alarm 
symptoms. The domiciliary education and attention 
have an important role in health since the declara-
tion of Alma-Ata in 1978, where its stated that health 
must be provided to the residence reside and work of 
people and that one of its main activities must be the 
education about the main health problems and pre-
vention methods, and the correspondent fight against 
the disease (19).
Health education is given by the nurse during the 
home visit and reinforced through a pamphlet de-
signed with simple language, which contains all the 
elements exposed in the visit. This domiciliary visit 
has demonstrated to be an ideal scenario to work on 
the health-disease process of the population, in their 
natural habitat, through the promotion of health and 
the prevention of the disease, allowing an exchange 
of information, experiences and abilities between the 
health staff and the users (20).   
Also, the patient or the caregiver is included in a 
WhatsApp group chat, administered by the nurse of 
the program, whose only purpose is for the patients or 
their family to consult about therapy questions, alarm 
symptoms or novelties that come up during the pro-
cess, this way guaranteeing a direct communication 
channel. 
In the punctual case of people in therapy with Warfa-
rin, the education provided in the home visit includes 
the specifications and the therapeutic target range es-
tablished by the INR, time of administration of the 
medicine, diet care, interactions with other medici-
nes, precautions with daily life activities and alarm 
symptoms.
Posterior to the home visit, an INR control and 
prothrombin time (PT) are performed every 72 hours 
during the first 10 days and later every month for the 
duration of the therapy. This control is performed im-
mediately through a device called coagulometer. 
The coagulometer is a portable biomedical equip-
ment, easy to use, which allows the rapid processing 
of blood tests, throwing specific results of levels of 
INR and PT. The system measures PT with only one 
drop of capillary blood processed by a strip with reac-
tive chemicals (21).
The result is reported by the nurse assistant, initially 
online through the WhatsApp application to all the 
health team members that lead the program, in a se-
cond group designed for this purpose, which allows 
immediate decisions and defining the next action. 
Through a phone call made by the nurse, the patient 
or family member receive the report of the INR and 
the indications to follow. This way, guaranteeing im-
mediate information to the patient, the family or the 
caregiver. According to each case, they receive indi-
cations of higher or lower doses of warfarin, suspen-
ding it or even moving the patient to the emergency 
service. Subsequently, it is registered in the medical 
history of the patient, which operates through a soft-
ware that can be accessed on any computer that has 
internet connection.  
If needed, additional check-up appointments are given 
and, finally, the interdisciplinary team meets monthly 
with the purpose of analyzing the clinical behavior 
of each person, in a process called clinical journal, 
which also stays registered in the medical history.
In this program, nursing care takes special importan-
ce, since it assumes that the fundamental pillar of care 
for the anticoagulation patient s health education, the 
permanent monitoring and a direct communication 
channel between the health workers and the patients. 
All these activities are responsibility of the professio-
nal nursing staff.
People with anticoagulation therapy different than 
Warfarin, meaning heparins of low molecular weight 
or new oral anticoagulants, also receive all the spe-
cific health education process for these medicines, 
home visits, follow-up of adherence, complications 
and periodic monitoring of renal physiology, that are 
taken at the residence and, as well as the last group, 
are presented monthly in the clinical journal
All the information is product of the behavior of the 
program, including results, indicators, news and ad-
justments, besides being registered on the medical 
history, it is also kept in a database that gives place 
to the monthly statistics of the program, whose analy-
sis motivated the development of the present study 
through the research question: what is the profile and 
results of the clinical indicators of people that are 
members of an anticoagulant domiciliary program in 
the city of Bogota, during a year of follow-up?
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This work justifies its results due to the lack of stu-
dies in literature that report results of anticoagulation 
programs performed in the residence of the patients. 
Domiciliary attention is new and, more frequently, is 
becoming an alternative for the care of people with 
diverse pathologies and the need for monitoring. 
Therefore, documenting these experiences through 
research takes great importance. 
Internationally some programs are described as ope-
rated by outpatient visits and led by pharmacists, who 
decreased hemorrhage rates and thromboembolic 
events. Also, its demonstrated that these can reduce 
the number of hospitalizations and visits to the emer-
gency room up to 73% (22).
The anticoagulation programs or clinics in Colombia 
have been constituted as a strategy legislated by the 
resolution 2003 of 2014 (17), within the services of 
specific protection or early detection, which are ex-
pected to favor a decrease of adverse events, improve 
the adherence to the treatment and lower hospitaliza-
tion days optimizing economic resources. Facing this 
situation, programs must be object of study for the 
interest of documenting the health results and impact 
in people.
Objective
Describe the profile and clinical indicators of people 
belonging to an anticoagulation domiciliary program 
in the city of Bogota, during a year of follow-up.
Materials and methods
Quantitative study of descriptive scope. The popula-
tion corresponded to t he total of people (99), attended 
for a year in a domiciliary anticoagulation program in 
the city of Bogota, between November 2016 and Oc-
tober 2017. The sample was made by 66 people who 
received uninterrupted therapy with warfarin only du-
ring the same year. 
The inclusion criteria were: being member of an an-
ticoagulation program at the healthcare provider that 
was object of study, being anticoagulated with war-
farin and have attended controls from the program 
uninterruptedly from November 2016 and October 
2017. Also, the exclusion criteria were: being anti-
coagulated with a therapy different from warfarin, 
having entered the program outside the established 
terms for the study or having interrupted controls due 
to hospitalization, moving to another city or death. 
The information was obtained from the monthly sta-
tistics, database, and indicators from the anticoagula-
tion program of the healthcare provider and consigned 
in an information matrix designed for this research. 
An independent statistical analysis was used, from 
the frequency distributions using Microsoft Office 
Excel 2013. For this process the following steps were 
made: 1) Identifying the admission profile of people 
to the anticoagulation program, formed by the va-
riables of age, gender, medical diagnosis, functional 
compromise, comorbidity index, INR of admission 
and risk classification of intermediate bleeding using 
the HAS-BLED Score. 2) Description of clinical in-
dicators which include the number of days to achieve 
the INR therapeutic target, percentage of the year in 
where the therapeutic range was maintained (time in 
therapeutic range) and the number of adverse events. 
This research respected the ethical principles for 
health research in Colombia, contemplated in the Re-
solution 8430 of 1993. It was considered a minimal 
risk research (23) and the respect for the dignity of 
people and human rights were guaranteed, reassuring 
that the recollected information would only be used 
with academic and scientific ends. The identity of the 
patients is reserved, omitting their names or identifi-
cation number. The study was put for consideration 
and approved by the university Research Ethics Com-
mittee, through the Act 013 from October 12, 2017., 
as well as the approval from the healthcare provider 
for the study. The people were informed about the 
program and accepted their voluntary participation 
by signing a consent agreement.
Also, intellectual property and copyright were gua-
ranteed by the Law 44 /1993.   
Results 
The total of people attended in the anticoagulation 
domiciliary program of the health care provider ob-
ject of study, during a process from November 2016 
to October 2017, was of 92. The most used type of 
therapy was Warfarin, with 72% of the total of pa-
tients (See Table 1).
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Table 3. Frequency distributions and percentages about the anticoagulation 
indication according to the medical diagnosis of the patients. Bogota, Colombia.
Medical diagnosis Frequency Percentage
AF 29 43,9 %
Stroke + AF+ mechanical mitral valve 11 16,7 %
Stroke + AF 7 10,6 %
Stroke+ DVT 7 10,6 %
Mechanical mitral valve prosthesis 5 7,6 %
PE 3 4,5 %
PE + DVT 3 4,5 %
DVT 1 1,5 %
Total 66 100,0 %
Source: Research results.
Table 1. Frequency distributions and percentages by type of 
anticoagulant of people attended by the domiciliary program. 
Bogota, Colombia. 
Type of anticoagulant Frequency Percentage
Apixaban 4 4,3 %
Dabigatran 6 6,5 %
Enoxaparin sodium 7 7,6 %
Rivaroxaban 9 9,8 %
Warfarin 66 71,7 %
Total 92 100 %
Source: Research results.
The 72% of people attended in the program for anti-
coagulation therapy with Warfarin that met the inclu-
sion criteria for this research corresponds to a total of 
66 patients, in which 70% were women and 30% men. 
In relation to age of the patients, it was found that 
1000% are older than 60 years, which significantly 
affects the morbidity and bleeding risk (See Table 2).
Table 2. Frequency distributions and percentages, according to the 
age range of the patients. Bogota, Colombia. 
Age range Frequency Percentage
61 to 70 years 11 16,7 %
71 to 80 years 22 33,3 %
81 to 90 years 30 45,5 %
91 to 100 years 3 4,5 %
Total 66 100,0%
Source: Research results.
In relation to anticoagulation indications, atrial fibri-
llation is the predominant phenomena with 43.9% of 
the cases, followed by ischemic stroke and DVT. It is 
important to notice that 42% of people present more 
than one indication of being anticoagulated, noticea-
bly compromising the comorbidity of this population 
(See Table 3).  
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To calculate the functional ability compromise, the 
Barthel scale was used and to calculate the comorbi-
dity the functional comorbidity index was considered 
(24). In that sense, 1005 of the population objects of 
study had a Barthel scale lower than 50, considered as 
severe and total dependence and a high comorbidity 
index, consequence of multiple pathologies. Regar-
ding the INR at the beginning of the program, 60% 
of people came to the program outside the therapeutic 
range, either due to under-anticoagulation or over an-
ticoagulation (See Table 4 ).
Table 4. Frequency distributions and percentages about the INR at 
the beginning of the anticoagulation domiciliary program. Bogota, 
Colombia.
INR Value Frequency Percentage
INR <1,9 (Subtherapeutic) 36 54,5 %
INR ENTRE 2 Y 3,5 (Therapeutic) 26 39,4 %
INR > 3,5 (Supratherapeutic) 4 6,1 %
Total 66 100,0 %
Source: Research results.
The bleeding risk was calculated through the HAS-
BLED scoring system. This score allows the determi-
nation of bleeding risk by analyzing variables such as 
blood pressure, renal and liver function, stroke prece-
dents, bleeding history, INR lability, age, use of medi-
cines and alcohol consumption. Each variable assigns 
a score and weighs the risk of bleeding as low, interme-
diate or high (25). In the specific case of this program, 
94% of people came with high and intermediate risk 
of bleeding, 54% showed a high risk of bleeding, 40% 
an intermediate risk of bleeding, and 6% low risk. Sin-
ce the admission to the domiciliary anticoagulation 
program and their uninterrupted permanence for 12 
months, the following results were obtained: 
Once the person is admitted to the program, INR and 
PT controls begin every 72 hours during the first days 
or until obtaining the therapeutic range. 80% of the 
people achieved their therapeutic target in the first 
9 days after being admitted and around 8% did not 
reach the target. These people, although getting con-
trol and accompaniment from the program were not 
able to reach the target, are reevaluated and rotated 
to direct anticoagulants or heparins of low molecular 
weight, according to indications (See table 5). 
Table 5. Frequency distributions and percentages about necessary 
controls to achieve the therapeutic range of the participants. Bogota, 
Colombia. 
Number of controls Frequency Percentage
1 28 42 %
2 24 36 %
3 8 12 %
4 2 3 %
8 1 2 %
Did not reach the range 3 5 %
Total 66 100 %
Source: Research results
The time in therapeutic range corresponds to the time 
the patient stays at the therapeutic target and consti-
tutes a tracing indicator by excellence of the success 
of the anticoagulant therapy (26). People attended in 
this program achieved a time in therapeutic range of 
70%, with at least 12 controls performed from Octo-
ber 2016 to November 2017.
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In relation to the proportion of adverse events as an 
indicator of security for the program, the results de-
monstrate that during the period of performance of 
this study, there were no adverse events requiring 
hospitalization, additional therapeutic interventions, 
presence of bleeding or new thrombotic events. 
Discussion
The anticoagulant therapy represents the cornerstone 
in the treatment and prevention of thrombotic disea-
ses and coagulation disorders, as stated Pantaleon and 
collaborators, showing that oral anticoagulants have 
demonstrated to be efficient for the prevention of 
thrombotic diseases. Its use has significantly increa-
sed and its currently considered as the medicine of 
preference for prevention and treatment, in the long 
term, of thrombosis or embolism (27).
The results of this study, where 70% of people atten-
ded are anticoagulated with warfarin, coincide with 
similar studies that assure that warfarin is the most 
used medicine, consequence of clinical experience 
and economic cost, in spite of its narrow margin of 
security, the need for permanent monitoring and in-
teraction with food and medicines, and parallel to the 
emergence of direct oral anticoagulants since 2008, 
as asserted by Bejarano et al. in a study performed in 
the city of Bogota (28).
Studies about the use of anticoagulants in Latin Ame-
rica confirm this information. Gamero et al., in a stu-
dy performed in Peru in 2017, found that 95% of peo-
ple with oral anticoagulation received warfarin and 
only 5% took direct oral anticoagulants, attributing 
this phenomenon to a subject of costs (29).
To that effect, a study lead by members of the Medi-
cine Faculty of the National University of Colombia, 
affirms that warfarin continues to be the most used 
oral anticoagulant in spite of its already known the-
rapeutic limitations. However, the use of direct oral 
anticoagulants is becoming more frequent in spite of 
the cost and the lack of availability in the Beneficial 
Health Plan (30).
The success of anticoagulant therapy and the reduc-
tion of preventable adverse events, specifically with 
the warfarin therapy, could be explained, in a large 
extent, to the health education and periodic monito-
ring of INR and PT, as well as the existence of a di-
rect channel of direct communication with the health 
team. This coincides with the results of a study made 
in Chile by Castro et al., who emphasize that the 
quality of the oral anticoagulant treatment is firmly 
related not only with the incidence of embolic and 
thrombosis complications but also with the gravity of 
these, being frequent monitoring necessary (31). In 
that sense, Miranda et al., agree with the monitoriza-
tion and the strict control of the anticoagulant thera-
py, reducing the risk of thrombotic events or bleeding 
(32). However, it is necessary to advance in the re-
search target of the studies to demonstrate the impact 
of the research programs, exceeding the descriptive 
and advancing towards the correlational and even 
towards the experimental areas, with a strict control 
of the variables.
The analysis of the gender distribution shows that 
two out of the three most frequent anticoagulation 
indications are mainly present in males. Therefore, 
atrial fibrillation is the most prevalent arrythmia and 
mainly affects men (33, 34), coinciding with the data 
from the Colombian Society of Cardiology and Car-
diovascular Surgery, the American Heart Association 
and the European Society of Cardiology (4), as well 
as the event of ischemic stroke (35), and, differing 
from deep vein thrombosis, which affects more wo-
men (36) than men. For being a program where more 
than 70% of the people exceeds 70 years of age, its 
most frequent to find women, given the characteris-
tics of life expectancy in Colombia, where the female 
gender lives longer (37). 
This study reports a time in therapeutic range of 70%, 
higher than in other studies such as the TERRA study 
made in Argentina, which analyzed data of time in 
therapeutic range of 14 anticoagulation programs and 
reported 66% (38). Meanwhile, in the study perfor-
med in the Fundacion de Santa Fe University Hos-
pital in Bogota, with a total of 159 patients, the time 
in therapeutic range obtained was of 53.7% (17). A 
similar result was obtained at the San Vicente Fun-
dacion de Medellin University Hospital, with 54% of 
time in therapeutic range, with more than 6 controls 
performed in the anticoagulation clinic (32).
Regarding the security indicators of the program, 
the results show that during the performance of this 
study no adverse events were present. However, the 
fact that the population achieved a time in therapeutic 
range of 70% means that 30% of the time this was 
outside the target, interpreting it as an incident. At 
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this point, it is important to emphasize that once the 
PT and INR controls are performed at the residence 
of the person and immediately reported, a convenient 
adjustment of the doses is allowed, limiting the event 
to an incident, constituting an original characteristic 
of this program. 
Agreeing with the latter, Somonetti et al., affirm that 
health promotion is a key strategy for the prevention 
of thromboembolic events in patients with oral anti-
coagulation therapy. In this context, the nurses and 
doctors perform the role of educators, particularly 
by providing a clear orientation about risk facts and 
possible signs and symptoms, also the complications 
related to anticoagulation (39).
Describing the characteristics of an anticoagulation 
domiciliary program -phenomena that is not found in 
literature-, takes special interest since the domiciliary 
environment is a new space in which health has been 
advancing, making more often the hospital visit the 
home of the patient and demonstrating a positive im-
pact in the health indicators, as affirmed by Gomez et 
al., who assure that domiciliary attention decreases 
the workload of the caregiver, favors the psychologi-
cal health of the patient, lowers the attention costs and 
improves the level of satisfaction of the users (40).  
Conclusions
• Warfarin is still the most used anticoagulant, due 
to clinical experience, cost and inclusion in the 
health benefits plan, despite the requirement of 
permanent monitoring, ample lability and inter-
action with other medicine and foods. 
• 70% of people attended at the program were 
women and 30% were men, exceeding the age of 
60. In relation to the anticoagulation indications, 
atrial fibrillation is the predominant phenomenon, 
followed by ischemic stroke and DVT. However, 
around 42% of people present more than one anti-
coagulation indication. 60% of people are admit-
ted outside the therapeutic range and 94% present 
intermediate and high risk of bleeding. 
• Subsequent to the admission to the anticoagula-
tion domiciliary program, 80% of the patients 
achieved their INR therapeutic target before the 
ninth day and around 8% did not accomplish the 
target, requiring rotation to direct oral anticoagu-
lants or heparins of low molecular weight.  
• A 70% of time in therapeutic range was achieved 
with at least 12 controls performed between Oc-
tober 2016 and November 2017 -a higher range 
compared to similar studies-, reaffirming the im-
portance of permanent monitoring, the existence 
of a direct communication channel between the 
patient, the family and the heath team from the 
program, the availability of additional controls 
and immediate adjustments at the residence, 
without needing to wait for a doctor´s appoint-
ment or having to move to the clinic or hospital.
• The PT + INR control performed at the residence 
of the patient and reported immediately to the 
health team, allows the appropriate adjustment 
of doses, preventing the emergence of adverse 
events and limiting these,  in the worst case sce-
nario, to an incident. 
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